Strategic site expansion in Brooklyn IGC Pharma has officially added Integrative Clinical Trials, located in Brooklyn, New York, as a key site for its ongoing Phase II CALMA clinical trial. By establishing a presence in a major metropolitan hub, the company aims to access a more diverse patient demographic, enhancing enrollment efficiency and the overall breadth of clinical data for its research programs.
Focus on IGC-AD1 for Alzheimer’s-related agitation The study evaluates IGC-AD1, an investigational cannabinoid-based therapeutic candidate designed to manage agitation in patients suffering from Alzheimer’s disease. The Phase II trial is being conducted as a randomized, double-blind, placebo-controlled study to maintain the highest standards of clinical evidence and safety monitoring.
AI integration and neurodegenerative pipeline Beyond physical site expansion, IGC Pharma utilizes artificial intelligence to optimize clinical trials, refine patient targeting, and accelerate the drug discovery process. Their current research pipeline spans multiple neurodegenerative mechanisms, including amyloid plaque targeting (TGR-63), tau protein dysfunctions, and metabolic-related neurodegeneration. Partnering with seasoned experts in central nervous system (CNS) disorders is a central component of the company’s strategy to streamline drug development and ensure high-quality data generation.